Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RRx-001 vs Regorafenib in Metastatic Colorectal Cancer
NCT02096354Phase 2Completed
- Sponsor
- EpicentRx
- Start
- May 2014
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Nibrozetone in colorectal cancer (CRC) (2 arms), sponsored by EpicentRx. Primary endpoint: Overall Survival. Started May 2014; status: completed.
02
Drugs
Nibrozetone
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02096354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096354.